7 Key Takeaways
-
1
Dana-Farber showcases faculty's recent research on cancer therapies.
-
2
LAG-3 is targeted for advanced melanoma therapy alongside PD-1 blockade.
-
3
Small cell lung cancer dependency on POU2F3 offers therapeutic insights.
-
4
The Breast Cancer Index is key for adjuvant treatment decisions in HR+ breast cancer.
-
5
Hypofractionated radiation shows promise in postmastectomy outcomes.
-
6
Circulating tumor DNA tests offer a new biomarker for recurrence in Merkel cell carcinoma.
-
7
Research highlights the need for precision oncology applications.
Dana-Farber's Research News highlights new studies by faculty members, featuring immune checkpoint therapy targeting LAG-3, the dependency of small cell lung cancer on POU2F3, and novel MET mutations that could guide targeted treatments in various cancers. A study emphasizes the utility of the Breast Cancer Index for enhancing therapy decisions in hormone receptor-positive breast cancer. Moreover, research on hypofractionated radiation post-mastectomy reveals quality-of-life impacts, while circulating tumor DNA signals promise for cancer progression monitoring across malignancies.
Listen Tab content
